Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
J&J (JNJ) Carvykti Gets EU Nod for Advanced Multiple Myeloma
01:53pm, Friday, 27'th May 2022 Zacks Investment Research
The European Commission approved J&J's (JNJ) BCMA-directed CAR-T cell therapy, Carvykti to treat patients with multiple myeloma who have already received multiple treatments.
7 Cheap Biotech Stocks to Buy Now
06:00pm, Thursday, 19'th May 2022
These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines. The post 7 Cheap Biotech Stocks to Buy Now appeared first on Inves
2 High-Risk, High-Reward Stocks for Contrarian Investors
03:23pm, Thursday, 19'th May 2022 The Motley Fool
Feeling adventurous?
2 High-Risk, High-Reward Stocks for Contrarian Investors
11:23am, Thursday, 19'th May 2022
Feeling adventurous?
These 5-Stock Samplers Have Gotten Whacked. And That's OK
02:32pm, Friday, 13'th May 2022 The Motley Fool
It's all part of investing.
bluebird (BLUE) Q1 Earnings and Sales Fall Short of Estimates
06:33pm, Tuesday, 10'th May 2022 Zacks Investment Research
bluebird's (BLUE) Q1 loss is worse than expected while sales lag estimates. It retains its dialogue with the FDA to resolve the clinical hold issue over its pipeline.
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
06:23pm, Tuesday, 10'th May 2022 Benzinga
RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and ha
bluebird (BLUE) Q1 Earnings and Sales Fall Short of Estimates
03:48pm, Tuesday, 10'th May 2022
bluebird's (BLUE) Q1 loss is worse than expected while sales lag estimates. It retains its dialogue with the FDA to resolve the clinical hold issue over its pipeline.
Analyst Ratings for bluebird bio
03:05pm, Tuesday, 10'th May 2022 Benzinga
Over the past 3 months, 6 analysts have published their opinion on bluebird bio (NASDAQ:BLUE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a co
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates
10:25pm, Monday, 09'th May 2022 Zacks Investment Research
Bluebird (BLUE) delivered earnings and revenue surprises of -31.75% and 86.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
bluebird bio: Beaten Down Biotech With Possible Long-Term Potential
01:59pm, Monday, 09'th May 2022
Potential to receive FDA approval of beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukoodystrophy in 2022. FDA approvals of beti-cel and eli-cel would give bluebird bio the ability to
One Biotech Stock to Hold; Another to Dump Right Now
11:30am, Saturday, 07'th May 2022
Biotech stocks have been successful in going public without revenues because the story of a pharmaceutical firm gaining FDA approval for a new drug is attractive to many investors.
Will Bluebird Bio (BLUE) Report Negative Q1 Earnings? What You Should Know
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Bluebird Bio (BLUE) Report Negative Q1 Earnings? What You Should Know
04:49pm, Wednesday, 27'th Apr 2022
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why bluebird bio (BLUE) Stock Plunged 60% Year to Date?
07:29pm, Friday, 22'nd Apr 2022 Zacks Investment Research
With no stable stream of income, bluebird bio (BLUE) faces a severe cash crunch. Moreover, the FDA extending the review period of its two regulatory filings also adds fuel to this fire.
